Media Report
March 12, 2012Crain's reports Karmanos researcher to co-lead 3-year, $6M national study of aggressive melanoma
http://www.crainsdetroit.com/article/20120311/SUB01/303119986/karmanos-researcher-co-leads-6m-national-study-of-aggressive-melanoma
The rising number of malignant melanoma cases the past four years at Karmanos Cancer Institute in Detroit illustrates the need for cutting-edge research into some of the most aggressive forms of the still mostly untreatable skin cancer. Patricia LoRusso, D.O., professor of oncology at Wayne State University’s School of Medicine and director of phase-one clinical trials and the institute's Eisenberg Center for Experimental Therapeutics, begins a three-year, $6 million research project as co-leader of a group of 50 cancer researchers at 12 medical centers who will study BRAF Wild-Type metastatic melanoma. "We know that there is a desperate need for treatment for those suffering from the most aggressive forms of the disease ... for which there are very few effective treatment options," said LoRusso. While only 150 patients will be studied nationwide at the 12 medical centers, including Karmanos, LoRusso said several other clinical studies on melanoma are in the works at Karmanos. "Melanoma has always been a tumor type of importance in our clinical program," LoRusso said.
The rising number of malignant melanoma cases the past four years at Karmanos Cancer Institute in Detroit illustrates the need for cutting-edge research into some of the most aggressive forms of the still mostly untreatable skin cancer. Patricia LoRusso, D.O., professor of oncology at Wayne State University’s School of Medicine and director of phase-one clinical trials and the institute's Eisenberg Center for Experimental Therapeutics, begins a three-year, $6 million research project as co-leader of a group of 50 cancer researchers at 12 medical centers who will study BRAF Wild-Type metastatic melanoma. "We know that there is a desperate need for treatment for those suffering from the most aggressive forms of the disease ... for which there are very few effective treatment options," said LoRusso. While only 150 patients will be studied nationwide at the 12 medical centers, including Karmanos, LoRusso said several other clinical studies on melanoma are in the works at Karmanos. "Melanoma has always been a tumor type of importance in our clinical program," LoRusso said.
Publications
- Crain's Detroit Business
Connect with WSU